Mark Devlin

Development of small molecule STING agonists that can evoke host anti-cancer immune defences following local or systemic delivery

Nicole Haynes, Theresa Connor, Ben Morrow, Judy Doherty, Matthew Dennis, Jonathan Hubert, Sukhdeep Spall, Anthony Cuzzupe, Karen White, Susan Charman, Aaron Lock, Vicky Avery, Stewart Nuttall, Tom Peat, Olan Dolezal, Pat Pilling, Jezrael Revalde, Tin Yow, Greg Arndt, Hendrik Falk, et al.

Conference Proceedings  |  2019  |  JOURNAL FOR IMMUNOTHERAPY OF CANCER

Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma

Shatha AbuHammad, Carleen Cullinane, Claire Martin, Zoe Bacolas, Teresa Ward, Huiqin Chen, Alison Slater, Kerry Ardley, Laura Kirby, Keefe T Chan, Natalie Brajanovski, Lorey K Smith, Aparna D Rao, Emily J Lelliott, Margarete Kleinschmidt, Ismael A Vergara, Anthony T Papenfuss, Peter Lau, Prerana Ghosh, Sue Haupt, et al.

Journal article  |  2019  |  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an established treatment in estrogen receptor-positive breast cancer and are c..

Highly fluorescent and HDAC6 selective scriptaid analogues

Cassandra L Fleming, Anthony Natoli, Jeannette Schreuders, Mark Devlin, Prusothman Yoganantharajah, Yann Gibert, Kathryn G Leslie, Elizabeth J New, Trent D Ashton, Frederick M Pfeffer

Journal article  |  2019  |  EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Fluorescent scriptaid analogues with excellent HDAC6 selectivity (HDAC1/6 > 500) and potency (HDAC6 IC50 < 5 nM) have been synthes..

EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications

SA Greenall, JF Donoghue, M Van Sinderen, V Dubljevic, S Budiman, M Devlin, I Street, TE Adams, TG Johns

Journal article  |  2015  |  ONCOGENE

A truncation mutant of the epidermal growth factor receptor, EGFRvIII, is commonly expressed in glioma, an incurable brain cancer...

A fluorescent histone deacetylase (HDAC) inhibitor for cellular imaging

Cassandra L Fleming, Trent D Ashton, Cameron Nowell, Mark Devlin, Anthony Natoli, Jeannette Schreuders, Frederick M Pfeffer

Journal article  |  2015  |  CHEMICAL COMMUNICATIONS

Fluorescence microscopy studies using 4-morpholinoscriptaid (4MS) demonstrated rapid cellular uptake of this scriptaid analogue in..

LIM kinase inhibition reduces breast cancer growth and invasiveness but systemic inhibition does not reduce metastasis in mice

Rong Li, Judy Doherty, Juliana Antonipillai, Sheng Chen, Mark Devlin, Kathryn Visser, Jonathan Baell, Ian Street, Robin L Anderson, Ora Bernard

Journal article  |  2013  |  CLINICAL & EXPERIMENTAL METASTASIS

Metastasis is the major cause of morbidity and mortality in cancer patients. An understanding of the genes that regulate metastasi..

Hepta and octapeptide agonists of protease-activated receptor 2

Mark G Devlin, Bernhard Pfeiffer, Bernadine Flanagan, Renee L Beyer, Thomas M Cocks, David P Fairlie

Journal article  |  2007  |  JOURNAL OF PEPTIDE SCIENCE

Protease-activated receptor 2 (PAR(2)) is a G protein-coupled cell surface receptor for trypsin-like enzymes. Proteolytic cleavage..

Initial support for the hypothesis that PAR(2) is involved in the immune response to Nippostrongylus brasiliensis in mice

Mark G Devlin, Robin B Gasser, Tom M Cocks

Journal article  |  2007  |  PARASITOLOGY RESEARCH

Protease-activated receptor 2 (PAR(2)) is a cell surface receptor that detects trypsin and trypsin-like enzymes. Although the prec..

Regulation of serotonin 5-HT2C receptors by chronic ligand exposure

MG Devlin, NJ Smith, OM Ryan, E Guida, PM Sexton, A Christopoulos

Journal article  |  2004  |  EUROPEAN JOURNAL OF PHARMACOLOGY

The effect of ligand pretreatment on human 5-hydroxytryptamine2C (5-HT2C) receptors was examined in CHO cells expressing high (CHO..